查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405831

高血压药物市场规模、份额和趋势分析报告：按药物类别、类型、给药途径、配销通路、地区和细分市场预测，2024-2030年

Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report By Drug Class (Diuretics, ACE Inhibitors), By Type (Primary, Secondary), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

高血压药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球高血压药物市场规模将达到306.9亿美元，2024年至2030年复合年增长率为3.91%。

高血压患者数量的增加是推动市场成长的主要因素。此外，肥胖、癌症和心臟病等慢性疾病的增加，以及药物研发和个人化医疗，正在推动高血压药物市场的成长。

正在研发的强大产品显示出良好的效果是推动抗高血压药物市场需求的主要因素。例如，2023 年 9 月，Alnylam Pharmaceuticals, Inc. 宣布其高血压药物 dilevesiran 的 2 期试验达到了主要终点，证明收缩压显着降低（24 小时平均值）。 Direvesiran 是一种针对血管紧张素原的 RNAi 疗法，给药，预计将针对需求未满足的人。

由于高血压是糖尿病的常见併发症，糖尿病盛行率的增加推动了高血压药物市场的成长。高血压是糖尿病的常见併发症，随着时间的推移，会损害心臟、血管、肾臟和其他器官。随着糖尿病盛行率的增加，抗高血压药物的需求也预计会增加。根据 IDF 糖尿病地图集 2021 年第 10 版，20 至 79 岁的成年人患有糖尿病的人数估计为 5.37 亿，预计到 2030 年将达到 6.43 亿。

政府对研发活动和分销的资助透过使高血压药物更便宜、改善可及性和增加竞争，在促进市场成长方面发挥了作用。例如，2023 年 8 月，Eazymed Technologies Pvt Ltd. 从印度泰米尔纳德邦新兴部门种子基金筹集了 50 万美元。该公司计划将这笔资金用于其供应链中的新业务，包括直接与製药公司合作以及扩大在二、三线城市的业务。这些倡议正在推动高血压药物市场的成长。

此外，新型高血压药物的核准增加预计将鼓励製药公司投资于新型有效治疗方法的研发，为主要参与者提供利润丰厚的机会。例如，2022年5月，FDA核准了Tyvaso DPI（曲前列环素）吸入粉剂。 Tyvaso DPI 是一种干粉吸入器，可将血管扩张剂曲前列环素直接输送至肺部。曲前列环素的作用是扩张肺动脉、降低肺部血压、提升运动能力。

高血压药物市场报告亮点

  • 按药物类别划分，钙拮抗由于其与其他抗高血压药物结合的固有特性，将在 2023 年占据市场主导地位。
  • 按类型划分，由于用餐、缺乏运动、肥胖、吸烟和过量饮酒等生活方式的改变以及老年人口的增加，原发性高血压药物在2023年占据了最大的市场份额。
  • 从给药途径来看，口服药物因其方便、有效和以患者为中心的方法占据了最大的市场份额。
  • 从配销通路来看，由于全球提供广泛医疗服务的医院数量不断增加，医院药房占据了市场主导地位。
  • 由于私人公司投资增加、有利的政府和保险政策、技术进步以及主要区域运营商，北美已建立了强大的区域地位，市场占有率为37.55%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素
    • 高血压和高血压盛行率增加
    • 老年人口增加
    • 开发新的、更有效的抗高血压药物
  • 市场抑制因素分析
    • 高血压药物的副作用
    • 监管挑战
  • 营商环境分析
    • SWOT 分析；按因素（政治/法律、经济/技术）
    • 波特五力分析

第四章 药品类别业务分析

  • 高血压药物市场：药物类别波动分析
  • 利尿剂
  • ACE抑制剂
  • 钙离子通道阻断剂
  • β-肾上腺素阻断剂
  • 血管扩张剂
  • 其他的

第五章业务分析的类型

  • 高血压药物市场：类型变异分析
  • 原发性高血压
  • 次发性高血压

第六章给药途径业务分析

  • 高血压药物市场：给药途径变化分析
  • 口服
  • 注射
  • 其他的

第七章配销通路业务分析

  • 高血压药物市场：配销通路波动分析
  • 零售药房
  • 医院药房
  • 网路药房

第八章区域业务分析

  • 2023年及2030年按地区分類的高血压药物市场占有率
  • 北美洲
    • 2018年至2030年北美高血压药物市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 2018年至2030年欧洲高血压药物市场估计与预测
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太地区高血压药物市场估计与预测
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018年至2030年拉丁美洲高血压药物市场估计与预测
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 2018-2030 年 MEA 高血压药物市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 参与企业概况
  • 财务绩效
  • 参与企业
    • 市场领导者
    • 2023年高血压药物市场占有率分析
    • 公司简介
    • 策略规划
Product Code: GVR-4-68040-166-1

Anti-hypertensive Drugs Market Growth & Trends:

The global anti-hypertensive drugs market size is expected to reach USD 30.69 billion by 2030, expandingat a CAGR of 3.91% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising patient base of high blood pressure is the primary factor propelling market growth. Moreover, increasing cases of chronic diseases such as obesity, cancer, and heart disease and innovations in drug discovery & personalized medicine are increasing the growth of anti-hypertensive drugs market.

Presence of strong product in the pipeline demonstrating positive results is a major factor driving the demand for anti-hypertensive drugs market. For instance, in September 2023, Alnylam Pharmaceuticals, Inc. announced the phase 2 study on an investigation drug for the treatment of hypertension, zilebesiran, met the primary end-point and demonstrated significant reduction in the systolic BP (24 hour mean). Zilebesiran is an RNAi therapeutic targeting angiotensinogen which is administered subcutaneously and is expected to target high unmet need in populations.

The growing prevalence of diabetes is fueling the anti-hypertensive drugs market growth, as hypertension is a common complication of diabetes. Over time, hypertension can damage the heart, blood vessels, kidneys, and other organs. As the prevalence of diabetes is growing, the demand for anti-hypertensive drugs is expected to increase. According to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults between the ages of 20-79 years are living with diabetes, and it is expected to reach 643 million by 2030.

Government funding for R&D activities and distribution is playing a role in boosting the market growth by making anti-hypertensive drugs more affordable, improving access, and increasing competition. For instance, in August 2023 , Eazymed Technologies Pvt Ltd. raised USD 500,000 from the Tamil Nadu Emerging Sector Seed Fund in India. The company will utilize the fund on new ventures in the supply chain, such as working directly with pharmaceutical companies to expand their presence in tier 2-3 cities. Such initiatives are boosting the anti-hypertensive drugs market growth.

Moreover, rising approvals of new anti-hypertensive drugs encourage pharmaceutical companies to invest in research & development of novel and effective treatment options, which is expected to offer lucrative opportunities for the key players. For instance, in May 2022, the FDA approved Tyvaso DPI (treprostinil) inhalation powder. Tyvaso DPI is a dry powder inhaler that delivers treprostinil, a vasodilator, directly to the lungs. Treprostinil works by dilating the pulmonary arteries, which reduces blood pressure in the lungs and improves exercise capacity.

Anti-hypertensive Drugs Market Report Highlights:

  • Based on drug class, the calcium channel blockers segment dominated the market in 2023 owing to their intrinsic property in combination with other anti-hypertensive drugs
  • Based on type, the primary hypertension segment held the largest segment share of the market in 2023, owing to the increasing geriatric population and changing lifestyle factors, such as diet, physical inactivity, obesity, smoking, and excessive alcohol consumption
  • Based on route of administration, the oral segment held the largest share due to its convenience, effectiveness, and patient-centered approach
  • Based on distribution channel, the hospital pharmacies dominated the market, owing to the rise in hospitals worldwide, offering a wide range of healthcare services
  • North America has established a strong regional position with a 37.55% market share owing to the increasing investment by private players, favorable government and insurance policies, technological advancements, and key regional operating players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Drug Class Snapshot
  • 2.3. Route of Administration and Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing the Prevalence of Hypertension and High Blood Pressure
    • 3.4.2. Growing Geriatric Population
    • 3.4.3. Development of New and More Effective Anti-Hypertensive Drugs
  • 3.5. Market Restraint Analysis
    • 3.5.1. Side Effects of Anti-Hypertensive Drugs
    • 3.5.2. Regulatory Challenges
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Drug Class Business Analysis

  • 4.1. Anti-hypertensive Drugs Market: Drug Class Movement Analysis
  • 4.2. Diuretics
    • 4.2.1. Diuretics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. ACE Inhibitors
    • 4.3.1. ACE Inhibitors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Calcium Channel Blockers
    • 4.4.1. Calcium Channel Blockers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Beta-adrenergic Blockers
    • 4.5.1. Beta-adrenergic Blockers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Vasodilators
    • 4.6.1. Vasodilators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Anti-hypertensive Drugs Market: Type Movement Analysis
  • 5.2. Primary Hypertension
    • 5.2.1. Primary Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Secondary Hypertension
    • 5.3.1. Secondary Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
  • 6.2. Oral
    • 6.2.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Injectables
    • 6.3.1. Injectables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
  • 7.2. Retail Pharmacy
    • 7.2.1. Retail Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Hospital Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Online Pharmacy
    • 7.4.1. Online Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Anti-hypertensive Drugs Market Share By Region, 2023 & 2030
  • 8.2. North America
    • 8.2.1. North America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Argentina Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Anti-hypertensive Drugs Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Sanofi
      • 9.3.3.1.1. Company Overview
      • 9.3.3.1.2. Financial Performance
      • 9.3.3.1.3. Product Benchmarking
      • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Boehringer Ingelheim International GmbH
      • 9.3.3.2.1. Company Overview
      • 9.3.3.2.2. Financial Performance
      • 9.3.3.2.3. Product Benchmarking
      • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Novartis AG
      • 9.3.3.3.1. Company Overview
      • 9.3.3.3.2. Financial Performance
      • 9.3.3.3.3. Product Benchmarking
      • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Johnson & Johnson Services, Inc.
      • 9.3.3.4.1. Company Overview
      • 9.3.3.4.2. Financial Performance
      • 9.3.3.4.3. Product Benchmarking
      • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. DAIICHI SANKYO COMPANY, LIMITED.
      • 9.3.3.5.1. Company Overview
      • 9.3.3.5.2. Financial Performance
      • 9.3.3.5.3. Product Benchmarking
      • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Merck & Co., Inc.
      • 9.3.3.6.1. Company Overview
      • 9.3.3.6.2. Financial Performance
      • 9.3.3.6.3. Product Benchmarking
      • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. AstraZeneca
      • 9.3.3.7.1. Company Overview
      • 9.3.3.7.2. Financial Performance
      • 9.3.3.7.3. Product Benchmarking
      • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Pfizer Inc.
      • 9.3.3.8.1. Company Overview
      • 9.3.3.8.2. Financial Performance
      • 9.3.3.8.3. Product Benchmarking
      • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. Lupin
      • 9.3.3.9.1. Company Overview
      • 9.3.3.9.2. Financial Performance
      • 9.3.3.9.3. Product Benchmarking
      • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Sun Pharmaceutical Industries Ltd.
      • 9.3.3.10.1. Company Overview
      • 9.3.3.10.2. Financial Performance
      • 9.3.3.10.3. Product Benchmarking
      • 9.3.3.10.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Anti-hypertensive Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 3 Global Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 North America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Canada Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Canada Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Canada Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Canada Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Europe Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 Europe Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Germany Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Germany Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Germany Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 UK Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 UK Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 UK Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 UK Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 France Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 France Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 35 France Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 France Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Italy Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Italy Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Italy Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Italy Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Spain Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Spain Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 43 Spain Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Spain Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Denmark Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 Denmark Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 Sweden Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Sweden Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Norway Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 Norway Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 Norway Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Norway Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 China Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 China Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 China Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 China Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Japan Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Japan Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Japan Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 Japan Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 India Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 71 India Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 72 India Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 India Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 South Korea Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 South Korea Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 77 South Korea Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Australia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 79 Australia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 80 Australia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 Australia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 83 Thailand Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 Thailand Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 Thailand Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Latin America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 89 Latin America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 92 Brazil Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Brazil Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Mexico Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 96 Mexico Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 97 Mexico Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 Mexico Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 100 Argentina Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 102 Argentina Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 109 South Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 111 South Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 116 UAE Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 117 UAE Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 118 UAE Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 119 UAE Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Anti-hypertensive Drugs Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Anti-hypertensive Drugs Market: Drug Class Movement Analysis
  • Fig. 15 Global Anti-hypertensive Drugs Market, by Diuretics, 2018 - 2030 (USD Million)
  • Fig. 16 Global Anti-hypertensive Drugs Market, by ACE Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 17 Global Anti-hypertensive Drugs Market, by Calcium Channel Blockers, 2018 - 2030 (USD Million)
  • Fig. 18 Global Anti-hypertensive Drugs Market, by Beta-adrenergic Blockers, 2018 - 2030 (USD Million)
  • Fig. 19 Global Anti-hypertensive Drugs Market, by Vasodilators, 2018 - 2030 (USD Million)
  • Fig. 20 Global Anti-hypertensive Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Anti-hypertensive Drugs Market: Type Movement Analysis
  • Fig. 22 Global Anti-hypertensive Drugs Market, by Primary Hypertension, 2018 - 2030 (USD Million)
  • Fig. 23 Global Anti-hypertensive Drugs Market, by Secondary Hypertension, 2018 - 2030 (USD Million)
  • Fig. 24 Global Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
  • Fig. 25 Global Anti-hypertensive Drugs Market, by Oral, 2018 - 2030 (USD Million)
  • Fig. 26 Global Anti-hypertensive Drugs Market, by Injectables, 2018 - 2030 (USD Million)
  • Fig. 27 Global Anti-hypertensive Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 28 Global Anti-hypertensive Drugs Market: Distribution Channel Movement Analysis
  • Fig. 29 Global Anti-hypertensive Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global Anti-hypertensive Drugs Market, by Hospital Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 31 Global Anti-hypertensive Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 Regional Outlook, 2023 & 2030
  • Fig. 34 Global Anti-hypertensive Drugs Market: Region Movement Analysis
  • Fig. 35 North America Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 China Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 India Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)